DecitaRel™(Decitabine) - LifeSciences
- AzatiRel® (Azacitidine)
- BortiRel® (Bortezomib)
- ErlotiRel® (Erlotinib)
- ImatiRel® (Imatinib)
- Isabis® (Sodium hyaluronate)
- LeuproRel® (Leuprolide)
- ReliCitabine® (Capecitabine)
- ReliDomide® (Lenalidomide)
- ReliTrexed® (Pemetrexed)
- SynoLife™ / SynoLife One™ (Hyaluronate Injection)
- TemoRel® (Temozolomide)
- TerliRel® (Terlipressin)
- SorafiRel™ (Sorafenib)
Business Pharmaceuticals DecitaRel
DecitaRel™ (Decitabine) exerts its antineoplastic effects after phosphorylation, causing hypomethylation of DNA and cellular differentiation, or apoptosis. Decitabine-induced hypomethylation in neoplastic cells, may restore normal function to genes, critical for the control of cellular differentiation and proliferation.
Decitabine is indicated for the treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated de novo and secondary MDS of all French-American-British subtypes and International Prognostic Scoring System groups of intermediate-1, intermediate-2 and high-risk.
DecitaRel™ (decitabine) is available in a vial as 50mg lyophilized powder for reconstitution and intravenous administration.